Skip to main content
SpringerLink
Log in

Human Papillomaviruses

  • Chapter
Global Virology I - Identifying and Investigating Viral Diseases

  • 2306 Accesses

Abstract

Human papillomavirus (HPV) is the most prevalent sexually transmitted infection worldwide and is strongly linked to cancers at multiple anatomic sites in both men and women. This chapter describes HPV structure, molecular biology, transmission, and immune response; examines the epidemiology of cervical, anal and oropharyngeal cancers; discusses key risk factors associated with acquisition and persistence of HPV infection, including HIV-coinfection; and highlights prevention and treatment approaches to invasive cervical, anal, and oropharyngeal HPV-related neoplasms. Increasing HPV vaccination globally among both females and males is showing promise in decreasing the global burden of HPV-associated malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19.

    PubMed Central  PubMed  Google Scholar 

  2. Pincock S. Virologist wins Nobel for cervical cancer discovery. Lancet. 2008;372(9647):1374.

    PubMed  Google Scholar 

  3. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.

    PubMed  Google Scholar 

  4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.

    PubMed Central  PubMed  Google Scholar 

  5. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans: Volume 90 Human papillomaviruses. Lyon: International Agency for Research on Cancer; 2007.

    Google Scholar 

  6. Baek JO, Seo JW, Kim IH, Kim CH. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography. Protein Expr Purif. 2011;75(2):211–7.

    CAS  PubMed  Google Scholar 

  7. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–302.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000;5(3):557–67.

    CAS  PubMed  Google Scholar 

  10. Buck CB, Day PM, Trus BL. The papillomavirus major capsid protein L1. Virology. 2013;445(1–2):169–74.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32 Suppl 1:S7–15.

    CAS  PubMed  Google Scholar 

  12. Feller L, Khammissa RA, Wood NH, Lemmer J. Epithelial maturation and molecular biology of oral HPV. Infect Agent Cancer. 2009;4:16.

    PubMed Central  PubMed  Google Scholar 

  13. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.

    PubMed  Google Scholar 

  14. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.

    CAS  PubMed  Google Scholar 

  15. Bonnez W. Papillomavirus. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical virology. 2nd ed. Washington, DC: ASM Press; 2002. p. 557–96.

    Google Scholar 

  16. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.

    PubMed  Google Scholar 

  17. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:11–25.

    Google Scholar 

  18. Reichman R. Human papillomavirus infections. In: DL K, E B, AS F, SL H, DL L, JL J, eds. Harrisons principles of internal medicine. Vol 16th ed. New York: Graw-Hill; 2005:1056–58.

    Google Scholar 

  19. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:1–10.

    Google Scholar 

  20. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78(21):11451–60.

    PubMed Central  PubMed  Google Scholar 

  21. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol. 2007;107(2 Suppl 1):S2–5.

    CAS  PubMed  Google Scholar 

  22. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 2009;5(2):e1000318.

    PubMed Central  PubMed  Google Scholar 

  23. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384(2):410–4.

    CAS  PubMed  Google Scholar 

  24. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5:F24–33.

    PubMed Central  PubMed  Google Scholar 

  25. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007;7(1):79–89.

    CAS  PubMed  Google Scholar 

  26. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212(4):356.

    CAS  PubMed  Google Scholar 

  27. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196(10):1447–54.

    PubMed  Google Scholar 

  28. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No.11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013: http://globocan.iarc.fr/. Accessed 6 Jan 2013.

  29. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.

    PubMed  Google Scholar 

  30. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349–59.

    CAS  PubMed  Google Scholar 

  31. Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine. 2012;30 Suppl 5:F1–11.

    PubMed  Google Scholar 

  32. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813–9.

    CAS  PubMed  Google Scholar 

  33. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004;189(1):46–50.

    PubMed  Google Scholar 

  34. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315–24.

    PubMed Central  PubMed  Google Scholar 

  35. Winer RL, Hughes JP, Feng Q, et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. 2011;20(4):699–707.

    PubMed Central  PubMed  Google Scholar 

  36. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513–7.

    PubMed Central  PubMed  Google Scholar 

  37. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010;70(8):3159–69.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3:S42–51.

    Google Scholar 

  39. The International Collaboration of Epidemiological Studies of Cervical C. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: Collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.

    Google Scholar 

  40. Calore EE, Cavaliere MJ, Calore NM. Squamous intraepithelial lesions in cervical smears of human immunodeficiency virus-seropositive adolescents. Diagn Cytopathol. 1998;18(2):91–2.

    CAS  PubMed  Google Scholar 

  41. Waller J, McCaffery KJ, Forrest S, Wardle J. Human papillomavirus and cervical cancer: issues for biobehavioral and psychosocial research. Ann Behav Med. 2004;27(1):68–79.

    PubMed  Google Scholar 

  42. Almonte M, Albero G, Molano M, Carcamo C, Garcia PJ, Perez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine. 2008;26 Suppl 11:L16–36.

    PubMed  Google Scholar 

  43. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis. 2005;191(11):1796–807.

    PubMed  Google Scholar 

  44. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis. 2002;186(6):737–42.

    PubMed  Google Scholar 

  45. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.

    CAS  PubMed  Google Scholar 

  46. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control. 2002;13(9):839–46.

    PubMed  Google Scholar 

  47. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case–control study. Cancer Causes Control. 2003;14(9):805–14.

    PubMed  Google Scholar 

  48. Luhn P, Walker J, Schiffman M, et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol. 2013;128(2):265–70.

    CAS  PubMed  Google Scholar 

  49. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002;94(18):1406–14.

    PubMed  Google Scholar 

  50. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–21.

    Google Scholar 

  51. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12–23.

    PubMed  Google Scholar 

  52. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine. 2008;26:K17–28.

    PubMed Central  PubMed  Google Scholar 

  53. National Cancer Institute. SEER Cancer Statistics Factsheets: Anal Cancer. 2013. http://seer.cancer.gov/statfacts/html/anus.html. Accessed 19 Jan 2014.

  54. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026–34.

    PubMed Central  PubMed  Google Scholar 

  55. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2550–6.

    PubMed Central  PubMed  Google Scholar 

  56. Nyitray AG. The epidemiology of anal human papillomavirus infection among women and men having sex with women. Sex Health. 2012;9(6):538–46.

    PubMed  Google Scholar 

  57. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183(3):383–91.

    CAS  PubMed  Google Scholar 

  58. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2011;203(1):49–57.

    PubMed Central  PubMed  Google Scholar 

  59. Shvetsov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis. 2009;48(5):536–46.

    PubMed Central  PubMed  Google Scholar 

  60. Moscicki AB, Ma Y, Farhat S, et al. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence. Clin Infect Dis. 2014;58(6):804–11.

    PubMed Central  PubMed  Google Scholar 

  61. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis. 2011;204(11):1711–22.

    PubMed Central  PubMed  Google Scholar 

  62. Glick SN, Feng Q, Popov V, Koutsky LA, Golden MR. High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis. 2014;209(3):369–76.

    PubMed Central  PubMed  Google Scholar 

  63. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965–73.

    PubMed  Google Scholar 

  64. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317(16):973–7.

    CAS  PubMed  Google Scholar 

  65. Holly EA, Whittemore AS, Aston DA, Ahn DK, Nickoloff BJ, Kristiansen JJ. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst. 1989;81(22):1726–31.

    CAS  PubMed  Google Scholar 

  66. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350–8.

    CAS  PubMed  Google Scholar 

  67. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol. 1994;139(8):772–80.

    CAS  PubMed  Google Scholar 

  68. Baranoski AS, Tandon R, Weinberg J, Huang FF, Stier EA. Risk factors for abnormal anal cytology over time in HIV-infected women. Am J Obstet Gynecol. 2012;207(2):107. e101–108.

    PubMed Central  PubMed  Google Scholar 

  69. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis. 2008;197(12):1676–84.

    PubMed  Google Scholar 

  70. Nyitray AG, Smith D, Villa L, et al. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis. 2010;201(10):1498–508.

    PubMed Central  PubMed  Google Scholar 

  71. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    CAS  PubMed  Google Scholar 

  72. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.

    PubMed  Google Scholar 

  73. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.

    CAS  PubMed  Google Scholar 

  74. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9.

    PubMed Central  PubMed  Google Scholar 

  75. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693–703.

    CAS  PubMed  Google Scholar 

  76. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013;382(9895):877–87.

    PubMed Central  PubMed  Google Scholar 

  77. Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev. 2012;21(1):122–33.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. D’Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer. 2007;121(1):143–50.

    PubMed  Google Scholar 

  79. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008;17(6):545–54.

    PubMed  Google Scholar 

  80. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012;24(5):506–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004;328(1):57–63.

    PubMed  Google Scholar 

  82. Rousseau MN, Costes V, Konate I, et al. Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso. J Med Virol. 2007;79(6):766–70.

    PubMed  Google Scholar 

  83. Baay MF, Kjetland EF, Ndhlovu PD, et al. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol. 2004;73(3):481–5.

    PubMed  Google Scholar 

  84. Temmerman M, Tyndall MW, Kidula N, Claeys P, Muchiri L, Quint W. Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. Int J Gynaecol Obstet. 1999;65(2):171–81.

    CAS  PubMed  Google Scholar 

  85. Gichangi PB, Bwayo J, Estambale B, et al. Impact of HIV infection on invasive cervical cancer in Kenyan women. AIDS. 2003;17(13):1963–8.

    PubMed  Google Scholar 

  86. Hawes SE, Critchlow CW, Sow PS, et al. Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. J Natl Cancer Inst. 2006;98(2):100–9.

    PubMed  Google Scholar 

  87. Vonau B, Boag F. HIV-positive women and cervical screening. Int J STD AIDS. 2000;11(12):767–73.

    CAS  PubMed  Google Scholar 

  88. Chin KM, Sidhu JS, Janssen RS, Weber JT. Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstet Gynecol. 1998;92(1):83–7.

    CAS  PubMed  Google Scholar 

  89. Centers for Disease Control and Prevention. AIDS-Defining Conditions. Morbidity and Mortality Weekly Report, MMWR. December 5, 2008;57(RR-10):9.

    Google Scholar 

  90. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20(18):2337–44.

    PubMed  Google Scholar 

  91. De Vuyst H, Ndirangu G, Moodley M, et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer. 2011;131(4):949–55.

    PubMed  Google Scholar 

  92. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487–500.

    PubMed  Google Scholar 

  93. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138(6):453–9.

    PubMed  Google Scholar 

  94. Sirera G, Videla S, Pinol M, et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. AIDS. 2006;20(8):1201–4.

    PubMed  Google Scholar 

  95. Kojic EM, Cu-Uvin S, Conley L, et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the Era of effective therapy (The SUN Study). Sex Transm Dis. 2011;38(4):253–9.

    PubMed  Google Scholar 

  96. Goncalves MA, Randi G, Arslan A, et al. HPV type infection in different anogenital sites among HIV-positive Brazilian women. Infect Agent Cancer. 2008;3:5.

    PubMed Central  PubMed  Google Scholar 

  97. Beachler DC, D’Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis. 2013;208(2):330–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177(2):361–7.

    CAS  PubMed  Google Scholar 

  99. Darwich L, Videla S, Canadas MP, et al. Distribution of human papillomavirus genotypes in anal cytological and histological specimens from HIV-infected men who have sex with men and men who have sex with women. Dis Colon Rectum. 2013;56(9):1043–52.

    PubMed  Google Scholar 

  100. Gonzalez C, Torres M, Benito A, et al. Anal squamous intraepithelial lesions are frequent among young HIV-infected men who have sex with men followed up at the Spanish AIDS Research Network Cohort (CoRIS-HPV). Int J Cancer. 2013;133(5):1164–72.

    CAS  PubMed  Google Scholar 

  101. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer. 2010;5:8.

    PubMed Central  PubMed  Google Scholar 

  102. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4(1):52–6.

    PubMed Central  PubMed  Google Scholar 

  103. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther. 2004;9(1):13–22.

    CAS  PubMed  Google Scholar 

  104. Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002;16(13):1799–802.

    CAS  PubMed  Google Scholar 

  105. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001;15(16):2157–64.

    CAS  PubMed  Google Scholar 

  106. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis. 2010;201(5):681–90.

    PubMed Central  PubMed  Google Scholar 

  107. Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003;188(1):128–36.

    PubMed  Google Scholar 

  108. Paramsothy PMPH, Jamieson DJMDMPH, Heilig CMP, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol. 2009;113(1):26–31.

    PubMed  Google Scholar 

  109. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis. 2001;184(5):547–51.

    CAS  PubMed  Google Scholar 

  110. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165(10):1143–53.

    PubMed  Google Scholar 

  111. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187–94.

    CAS  PubMed  Google Scholar 

  112. Cameron JE, Mercante D, O’Brien M, et al. The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sex Transm Dis. 2005;32(11):703–9.

    PubMed  Google Scholar 

  113. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007;45(4):510–3.

    PubMed  Google Scholar 

  114. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res. 2006;19(1):99–105.

    CAS  PubMed  Google Scholar 

  115. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42.

    PubMed  Google Scholar 

  116. Denny L. Prevention of cervical cancer. Reprod Health Matters. 2008;16(32):18–31.

    PubMed  Google Scholar 

  117. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright Jr TC. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005;294(17):2173–81.

    CAS  PubMed  Google Scholar 

  118. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.

    PubMed  Google Scholar 

  119. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370(9585):398–406.

    PubMed  Google Scholar 

  120. Sankaranarayanan R, Shyamalakumary B, Wesley R, Sreedevi Amma N, Parkin D, Nair M. Visual inspection with acetic acid in the early detection of cervical caner and precursors. Int J Cancer. 1999;80(1):161.

    CAS  PubMed  Google Scholar 

  121. Shastri SS, Dinshaw K, Amin G, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ. 2005;83(3):186–94.

    PubMed Central  PubMed  Google Scholar 

  122. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335(7609):28.

    PubMed Central  PubMed  Google Scholar 

  123. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88–105.

    PubMed  Google Scholar 

  124. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929–36.

    PubMed  Google Scholar 

  125. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94.

    CAS  PubMed  Google Scholar 

  126. Flores YN, Bishai DM, Lorincz A, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes Control. 2011;22(2):261–72.

    PubMed Central  PubMed  Google Scholar 

  127. Sroczynski G, Schnell-Inderst P, Muhlberger N, et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany–a decision analysis. Eur J Cancer. 2011;47(11):1633–46.

    CAS  PubMed  Google Scholar 

  128. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–72.

    CAS  PubMed  Google Scholar 

  129. American Society for Colposcopy and Cervical Pathology (ASCCP). 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. 2009 addendum. 2009. http://www.guideline.gov/content.aspx?id=14698. Accessed 7 Feb 2014.

  130. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol. 2009;45 Suppl 1:S3–12.

    PubMed  Google Scholar 

  131. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.

    PubMed  Google Scholar 

  132. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine. 2012;30 Suppl 5:F100–6.

    CAS  PubMed  Google Scholar 

  133. Cuzick J, Bergeron C, von Knebel DM, et al. New technologies and procedures for cervical cancer screening. Vaccine. 2012;30 Suppl 5:F107–16.

    CAS  PubMed  Google Scholar 

  134. Evaluate Ltd. QIAGEN Announces Commercial Launch of CareHPV Test in China. 2013; http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=420248. Accessed 7 Feb 2014.

  135. U.S. Preventive Services Task Force. Screening for Cervical Cancer. U.S. Preventive Services Task Force Recommendation Statement. 2012; http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerrs.htm. Accessed 25 Jan 2014.

  136. World Health Organization (WHO). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. . WHO Guidelines. 2013. http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/. Accessed 10 Feb 2014.

  137. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11(4):201–301.

    PubMed  Google Scholar 

  138. Panel on Opportunitistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2013.

    Google Scholar 

  139. Centers for Disease Control and Prevention (CDC). USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immuno-deficiency virus: a summary. MMWR Morb Mortal Wkly Rep. 1995;44:1-34.

    Google Scholar 

  140. Smyczek P, Singh AE, Romanowski B. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013;24(11):843–51.

    PubMed  Google Scholar 

  141. Ortoski RA, Kell CS. Anal cancer and screening guidelines for human papillomavirus in men. J Am Osteopath Assoc. 2011;111(3 Suppl 2):S35–43.

    PubMed  Google Scholar 

  142. US Dept of Health and Human Services (DHHS) Health Resources and Services Administration HIV/AIDS Bureau. Anal Dysplasia. Guide for HIV/AIDS Clinical Care 2011; http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11/cg-607_anal_dysplasia.html. Accessed 25 Jan 2014, 2014.

  143. Kreimer AR, Chaturvedi AK. HPV-associated oropharyngeal cancers–are they preventable? Cancer Prev Res (Phila). 2011;4(9):1346–9.

    Google Scholar 

  144. Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal “pap-test equivalent” in high-risk populations. Cancer Prev Res (Phila). 2011;4(9):1378–84.

    Google Scholar 

  145. Affairs ACoS. Statement on Human Papillomavirus and Squamous Cancers of the Oropharynx. 2013; http://www.ada.org/1749.aspx. Accessed 9 Jan 2014, 2014.

  146. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Morbidity and Mortality Weekly Report, MMWR. April 10, 2009;58(RR-4):68.

    Google Scholar 

  147. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. 2002;287(16):2114-2119.

    Google Scholar 

  148. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–85.

    CAS  PubMed  Google Scholar 

  149. FUTURE_II_Study_Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England J Med. 2007;356(19):1915–27.

    Google Scholar 

  150. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–70.

    CAS  PubMed  Google Scholar 

  151. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401–11.

    CAS  PubMed Central  PubMed  Google Scholar 

  152. Erickson BK, Landers EE, Huh WK. Update on Vaccination Clinical Trials for HPV-Related Disease. Clin Ther. 2014;36(1):8–16.

    PubMed  Google Scholar 

  153. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59(20):626–29.

    Google Scholar 

  154. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.

    PubMed  Google Scholar 

  155. Centers for Disease Control and Protection (CDC). Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older—United States, 2014. Morbidity and Mortality Weekly Report. 2014;Suppl/Vol 63(Feb 7):108-112.

    Google Scholar 

  156. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802.

    CAS  PubMed  Google Scholar 

  157. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8(3):390–7.

    PubMed  Google Scholar 

  158. US Food and Drug Administration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 2014; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm. Accessed March 8, 2015, 2015.

  159. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723.

    Google Scholar 

  160. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. The Journal of infectious diseases. 2013;208(3):385–393.

    Google Scholar 

  161. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2010.

    Google Scholar 

  162. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–547.

    Google Scholar 

  163. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. American journal of public health. 2012;102(5):833–835.

    Google Scholar 

  164. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109–113.

    Google Scholar 

  165. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–2092.

    Google Scholar 

  166. Herrero R, Quint W, Hildesheim A, et al. Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS One. 2013;8(7):e68329.

    Google Scholar 

  167. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.

    Google Scholar 

  168. Centers for Disease Control and Prevention (CDC). National and State Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685–693.

    Google Scholar 

  169. Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics. 2011;128(5):830–839.

    Google Scholar 

  170. Pierce Campbell CM, Menezes LJ, Paskett ED, Giuliano AR. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1402–1408.

    Google Scholar 

  171. Al-Dubai SA, Alshagga MA, Al-Naggar RA, et al. Knowledge, attitudes and barriers for human papilloma virus (HPV) vaccines among Malaysian women. Asian Pac J Cancer Prev. 2010;11(4):887–892.

    Google Scholar 

Download references

Acknowledgments

None

Potential Conflicts of Interest: The authors have no potential conflicts of interest to report.

Author information

Authors and Affiliations

  1. Division of Infectious Disease and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 1 Tampa General Circle, Room G318, Tampa, FL, 33606, USA

    Lynette J. Menezes Ph.D., Jamie P. Morano M.D., M.P.H. & Leela Mundra B.A.

Authors
  1. Lynette J. Menezes Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamie P. Morano M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leela Mundra B.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynette J. Menezes Ph.D. .

Editor information

Editors and Affiliations

  1. Division of Infectious Diseases and International Medicine, USF Morsani College of Medicine, Tampa, Florida, USA

    Paul Shapshak

  2. Infectious Diseases and International He, USF Morsani College of Medicine, Tampa, Florida, USA

    John T. Sinnott

  3. Division of Infectious Diseases and Inte, USF Morsani College of Medicine, Tampa, Florida, USA

    Charurut Somboonwit

  4. C.W. Bill Young Center for Biodefense & Emerging Infectious Diseases, NIH-NIAID Div. Clinical Research, Frederick, Maryland, USA

    Jens H. Kuhn

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Menezes, L.J., Morano, J.P., Mundra, L. (2015). Human Papillomaviruses. In: Shapshak, P., Sinnott, J., Somboonwit, C., Kuhn, J. (eds) Global Virology I - Identifying and Investigating Viral Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2410-3_2

Download citation

Publish with us

Policies and ethics

Search

Navigation